In less than two decades, the median progression-free survival (PFS) for a standard-risk multiple myeloma patient has dramatically increased from 3-5 years in 2006 to a projected 15-16 years today. This leap is largely attributed to the introduction of quadruplet regimens, particularly those including anti-CD38 antibodies.
The profound success of anti-CD38 antibodies like daratumumab isn't just due to their direct anti-myeloma effect. A key part of their efficacy comes from altering the tumor microenvironment by reducing immunosuppressive T-regulatory cells and expanding anti-tumor T-cell clones, creating a synergistic effect.
When choosing between BCMA-directed therapies, using CAR-T therapy first may be strategically advantageous. Early evidence suggests continuous T-cell engager (bispecific) therapy may exert more selective pressure, leading to a higher risk of BCMA target loss through mutation or deletion compared to one-time CAR-T infusions.
Next-generation CELMoDs (iberdomide, mezagdomide) show promise beyond direct tumor killing. Their ability to reduce or reverse T-cell exhaustion suggests they could be used to 'prime' a patient's immune system, potentially restoring function before or after treatment with a CAR-T or bispecific T-cell engager.
The durability of CAR-T responses is prompting a paradigm shift. With a plateau forming on survival curves, where a third of heavily pretreated patients remain relapse-free five years post-infusion, experts are now seriously discussing how to formally define a 'cure' for multiple myeloma.
Giving prophylactic tocilizumab before bispecific antibody administration is a highly effective strategy to mitigate Cytokine Release Syndrome (CRS). This approach can reduce CRS rates from ~70% to 5-14%, making outpatient step-up dosing a much more feasible and safer option for community oncology centers.
GPRC5D-targeting bispecifics like talquetamab require a specific learning curve due to their unique 'on-target, off-tumor' side effects. Because the GPRC5D target is also present on skin and taste bud tissues, patients can experience significant dysgeusia, skin changes, and nail toxicities that require active management.
Within the next 3-5 years, the treatment paradigm for newly diagnosed myeloma will likely shift to upfront CAR-T and bispecific therapies. Experts believe this will enable fixed-duration treatments with curative intent, ultimately diminishing the role of autologous stem cell transplant, particularly in the United States.